Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy

Fig. 2

A response to haplo-CAR T cell therapy. a Treatments and the white blood cell changes during perio-haplo-CAR T cell therapy. The first infusion day of haplo-identical CAR T cells was as day 0, rituximab (R) 375 mg/m2 was used at day − 19 and 500 mg/m2 at day − 13 and − 6 before infusion (red font). Venetoclax 400 mg daily was used from day − 11 to day − 1 before infusion (red line). The treatment with ibrutinib 560 mg daily lasted from day − 19 to day − 1 before infusion (blue line). b Treatments and the white blood cell changes during haplo-CAR T cell therapy. The red triangle represents the number of lymphocytes (L) and monocytes (M), blue square represents the level of neutrophile granulocytes (N). Fludarabine (F) 25 mg/m2 and cyclophosphamide (C) 20 mg/kg was used on day − 4 and − 2 before infusion (red font). Haplo-identical CART22 cells were infused from day 0 to day 2, while haplo-identical CART20 cells were infused on day 2 and day 3. From day 9, ibrutinib (red line) and venetoclax (blue line) were used again. c In vitro tumor-cytotoxicity effect of haplo-identical CART20 and CART22 cells at an effector/target ratio of 25:1, 5:1 and 1:1 respectively. d and e Levels of IL-6 and ferritin after haplo-CAR T cell therapy. f and g CAR T cell number and copies of lentivirus-containing CAR in the peripheral blood after haplo-CAR T cell therapy. h The ratio of CD4+/CD8+ T cells in the peripheral blood was 1.6 at day + 7 and 0.4 at day + 14

Back to article page